Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

Phase 3 Not yet recruiting 520 enrolled Tasly Pharmaceutical Group Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)

Timeline

Start: 2024-12-30
Primary completion: 2026-11-11
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Changkang granules	Unknown	7.5 g	Oral

Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

Summary

Timeline

Drugs

Indications